1. Altered trajectories of neurodevelopment and behavior in mouse models of Rett syndrome.
- Author
-
Smith, Elizabeth S., Smith, Dani R., Eyring, Charlotte, Braileanu, Maria, Smith-Connor, Karen S., Ei Tan, Yew, Fowler, Amanda Y., Hoffman, Gloria E., Johnston, Michael V., Kannan, Sujatha, and Blue, Mary E.
- Subjects
- *
RETT syndrome , *NEURAL development , *GENETIC models , *GENETIC code , *TRANSGENIC mice , *ANIMAL models in research , *ANIMAL behavior , *NEUROPLASTICITY - Abstract
• Structural changes in MeCP2 deficient mouse models are similar to those in RTT. • Region-specific modifications in structure often coincide with phenotype onset. • Whisker follicle plasticity within the barrel cortex is altered by MeCP2 deficiency. • MeCP2 has non-cell autonomous effects on neuronal and glial structure and function. Rett Syndrome (RTT) is a genetic disorder that is caused by mutations in the x-linked gene coding for methyl-CpG-biding-protein 2 (MECP2) and that mainly affects females. Male and female transgenic mouse models of RTT have been studied extensively, and we have learned a great deal regarding RTT neuropathology and how MeCP2 deficiency may be influencing brain function and maturation. In this manuscript we review what is known concerning structural and coinciding functional and behavioral deficits in RTT and in mouse models of MeCP2 deficiency. We also introduce our own corroborating data regarding behavioral phenotype and morphological alterations in volume of the cortex and striatum and the density of neurons, aberrations in experience-dependent plasticity within the barrel cortex and the impact of MeCP2 loss on glial structure. We conclude that regional structural changes in genetic models of RTT show great similarity to the alterations in brain structure of patients with RTT. These region-specific modifications often coincide with phenotype onset and contribute to larger issues of circuit connectivity, progression, and severity. Although the alterations seen in mouse models of RTT appear to be primarily due to cell-autonomous effects, there are also non-cell autonomous mechanisms including those caused by MeCP2-deficient glia that negatively impact healthy neuronal function. Collectively, this body of work has provided a solid foundation on which to continue to build our understanding of the role of MeCP2 on neuronal and glial structure and function, its greater impact on neural development, and potential new therapeutic avenues. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF